20 (AIDX) Revenue (2025 - 2026)
20's (AIDX) quarterly Revenue came in at $730571.0 in Q2 2026, up 36.54% on a YoY basis from $535060.0 in Q2 2025, and up 106.74% quarter-over-quarter from $353375.0 in Q1 2026.
Powered by 
Analysis
20 (AIDX) Revenue (2025 - 2026) Analysis & Trends
20 (AIDX) has reported Revenue for 2 consecutive years, with $730571.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Revenue rose 36.54% year-over-year to $730571.0; the trailing twelve-month figure through Jun 2026 stood at $2.2 million (changed N/A YoY), and the FY2025 full-year result was $2.0 million, up 16.71% from the prior year.
- Revenue improved to $730571.0 in Q2 2026 per AIDX's latest filing, from $353375.0 in the prior quarter.
- Across five years, Revenue topped out at $730571.0 in Q2 2026 and bottomed at $353375.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Natera | 46.97 Bn | 45.87 Bn | 486.15 Mn | 752.75 Mn |
| 2 | Labcorp Holdings | 26.34 Bn | 26.19 Bn | 1.11 Bn | 3.73 Bn |
| 3 | Quest Diagnostics | 25.88 Bn | 25.25 Bn | 1.03 Bn | 3.04 Bn |
| 4 | Guardant Health | 22.04 Bn | 20.99 Bn | 219.03 Mn | 334.98 Mn |
| 5 | Tempus AI | 11.19 Bn | 10.37 Bn | 274.25 Mn | 382.49 Mn |
| 6 | Caris Life Sciences | 6.99 Bn | 6.19 Bn | 182.38 Mn | 263.71 Mn |
| 7 | Sotera Health | 5.25 Bn | 4.90 Bn | 177.96 Mn | 321.38 Mn |
| 8 | BillionToOne | 4.68 Bn | 4.13 Bn | 77.11 Mn | 109.45 Mn |
| 9 | iRhythm Holdings | 4.00 Bn | 3.41 Bn | 163.21 Mn | 224.17 Mn |
| 10 | 20 | 6.16 Mn | 1.62 Mn | 304,727.00 | 730,571.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 730,571.00 |
| Mar 31, 2026 | 353,375.00 |
| Jun 30, 2025 | 535,060.00 |
| Mar 31, 2025 | 553,820.00 |